Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Diagnostics and laboratory products / Molecular and specialised diagnostics / Complex genomic and specialised testing for inherited disease and oncology profiling

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Complex genomic and specialised testing for inherited disease and oncology profiling

Sequencing-based and array/PCR-plus-molecular specialty products used to diagnose inherited and rare conditions and to profile tumour genomics for targeted therapy selection, including hereditary cancer panels, exome/genome sequencing, tumour tissue and liquid-biopsy profiling, and the associated reagents, kits and interpretation services. Job to be done: produce an analytically and clinically valid, interpretable answer for a complex or treatment-contingent case that routine and rapid panels cannot deliver.

Market size
$7.3B
$7.3B ($5.6B–$9.0B) · 2025 · Triangulated
Growth
+10.0%
$11.7B by 2030
Attractiveness
— /100
for B2B sellers
Evidence
Low confidence
6 sources · Triangulated
Level
Niche
Segmented by
Customer type
Buyers
Specialised diagnostic providers (reference laboratories, molecular pathology labs) and hospital laboratories operating referral/genomic testing services
Buying centre
Molecular pathology and laboratory medicine leadership with clinical genetics and oncology input; purchasing via multi-year reagent/service contracts, with payer and guideline bodies (coverage policies) as an external decision gate.
Buying triggers
  • Expansion of national or regional hereditary cancer and rare-disease screening programmes
  • Targeted-therapy and companion-diagnostic launches requiring tumour profiling
  • Guidelines and payer coverage decisions for hereditary and somatic testing
  • Turnaround-time and sample-quality requirements for referral testing
Pains
  • Reimbursement and coding gaps for hereditary and rare-disease testing
  • Long turnaround times and sample logistics failures in referral testing
  • Interpretation workload and clinical validity/utility evidence burden
  • Cost per sample of NGS workflows and consumables versus panel economics
Scores (1–5)
Pain intensity—
Purchasing power—
Reachability5
Growth—

How this was sized

$7.3B ($5.6B–$9.0B) · 2025 · Triangulated

Same USD 22.0B submarket pool (see niche 1 notes). Complex genomic and specialised testing assumed 33% of the submarket = USD 7.26B (range 5.6-9.0B). Forecast: 7,260 x 1.10^5 = USD 11,690M in 2030. 10.0% CAGR is above the 4.78% clinical diagnostics CAGR [1] and the 6.6% diagnostic tests CAGR [3], reflecting molecular mix gain and oncology/hereditary testing adoption; North America alone held 40.0% of clinical diagnostics value in 2025 [1], so this niche is geographically concentrated. Low confidence: the 33% allocation is an assumption; no source in the set sizes molecular diagnostics directly.

Alongside it in Molecular and specialised diagnostics

// Sell into Complex genomic and specialised testing for inherited disease and oncology profiling

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.